# Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

> **NCT02180204** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Reza Behrouz, DO**

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Tenecteplase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT02180204
- **Lead sponsor:** Reza Behrouz, DO
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180204, "Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02180204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*